section name header

Information

Acute endocarditis is a febrile illness that rapidly damages cardiac structures, seeds extracardiac sites hematogenously, and can progress to death within weeks. Subacute endocarditis follows an indolent course, rarely causes metastatic infection, and progresses gradually unless complicated by a major embolic event or a ruptured mycotic aneurysm.

TREATMENT

Endocarditis

ANTIMICROBIAL THERAPY

  • Antimicrobial therapy must be bactericidal and prolonged. See Table 83-2 Antibiotic Treatment for Infective Endocarditis Caused by Common Organismsa for organism-specific regimens.
    • Blood cultures should be repeated until sterile. Results should be rechecked if there is recrudescent fever and at 4-6 weeks after therapy to document cure.
    • If pts are febrile for 7 days despite antibiotic therapy, an evaluation for paravalvular or extracardiac abscesses should be performed.
  • Pts with acute endocarditis require antibiotic treatment as soon as three sets of blood culture samples are obtained, but pts with subacute disease who are clinically stable should have antibiotics withheld until a diagnosis is made.
  • Pts treated with vancomycin or an aminoglycoside should have serum drug levels monitored. Tests to detect renal, hepatic, and/or hematologic toxicity should be performed periodically.

ORGANISM-SPECIFIC THERAPIES

  • Endocarditis due to group B, C, or G streptococci should be treated with the regimen recommended for relatively penicillin-resistant streptococci (Table 83-2 Antibiotic Treatment for Infective Endocarditis Caused by Common Organismsa ).
  • Killing of enterococci requires the synergistic activity of a cell wall-active agent and an aminoglycoside (gentamicin or streptomycin) to which the isolate does not exhibit high-level resistance. If toxicity develops after 2-3 weeks of treatment, the aminoglycoside can be discontinued in pts who have responded satisfactorily. If there is high-level resistance to both aminoglycosides, the cell wall-active agent should be given alone for 8-12 weeks, or-for Enterococcus faecalis-high-dose ampicillin plus ceftriaxone or cefotaxime can be given. If the isolate is resistant to all commonly used agents, surgical therapy is advised (see next and Table 83-3 Timing of Cardiac Surgical Intervention in Pts with Endocarditis ).
  • For staphylococcal NVE, the addition of 3-5 days of gentamicin to a β-lactam antibiotic does not improve survival rates and is not recommended.
  • Although this regimen has not yet been approved by the FDA, daptomycin (8-10 mg/kg IV qd) has been effective for endocarditis caused by S. aureus isolates with a vancomycin MIC of 2 µg/mL. These isolates should be tested to document daptomycin sensitivity.
  • Staphylococcal PVE is treated for 6-8 weeks with a multidrug regimen. Rifampin is important because it kills organisms adherent to foreign material. The inclusion of two other agents in addition to rifampin helps prevent the emergence of rifampin resistance in vivo. Testing for gentamicin susceptibility should be performed before rifampin is given; if the strain is resistant, another aminoglycoside, a fluoroquinolone, ceftaroline, or another active agent should be substituted.
  • Empirical therapy (either before culture results are known or when cultures are negative) depends on epidemiologic clues to etiology (e.g., endocarditis in an IV drug user, health care-associated endocarditis).
    • In the setting of no prior antibiotic therapy and negative blood cultures, S. aureus, CoNS, and enterococcal infection are unlikely; empirical therapy in this situation should target nutritionally variant organisms, the HACEK group, and Bartonella.
    • If negative cultures are confounded by prior antibiotic therapy, broader empirical therapy is indicated and should cover pathogens inhibited by the prior therapy.

SURGICAL TREATMENT

  • The timing and indications for surgical intervention are listed in Table 83-3 Timing of Cardiac Surgical Intervention in Pts with Endocarditis ; most of these indications are not absolute, and recommendations are derived from observational studies and expert opinion. Moderate or severe refractory CHF is the major indication for surgical treatment of endocarditis.
  • Cardiac surgery should be delayed for 2-3 weeks if possible when the pt has had a nonhemorrhagic embolic stroke and for 4 weeks when the pt has had a hemorrhagic embolic stroke. Ruptured mycotic aneurysms should be treated prior to cardiac surgery.
  • The duration of antibiotic therapy after cardiac surgery depends on the indication for surgery.
    • For cases of uncomplicated NVE caused by susceptible organisms with negative valve cultures at surgery, the duration of pre- and postoperative treatment should equal the total duration of recommended therapy, with 2 weeks of treatment given postoperatively.
    • For endocarditis with paravalvular abscess, partially treated PVE, or culture-positive valves, pts should receive a full course of therapy postoperatively.
  • Outcome: Death and other poor outcomes are related not to failure of antibiotic therapy but rather to interactions of comorbidities and endocarditis-related end-organ complications.
    • Survival rates are 85-90% for NVE due to viridans streptococci, HACEK organisms, or enterococci as opposed to 55-70% for NVE due to S. aureus in pts who are not IV drug users.
    • PVE beginning within 2 months of valve replacement results in mortality rates of 40-50%, whereas rates are only 10-20% in later-onset cases.
  • Prevention: The American Heart Association and the European Society of Cardiology have narrowed recommendations for antibiotic prophylaxis, limiting its use to pts at highest risk of severe morbidity and death from endocarditis.

Outline

Section 7. Infectious Diseases